A recent study reveals that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Research printed in a prominent health publication demonstrates that while obese individuals can lose about a fifth of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"Users using such treatments need to be aware of the danger of fast rebound weight gain when the medication ends," stated lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment mass within about one and a half years.
Analyzing Approaches
The study, which examined 37 of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with conventional dieting.
The team point out that people who shed pounds through diet and exercise usually have a slower creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Doctors suggest the mode of action of the jabs explains the amplified regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the body to produce less of its own natural hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication leads to appetite is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
Health authorities suggest the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, given the high risk of relapse, the therapy should be considered long-term.
This perspective is supported by drug manufacturers, who note that the results "underscore the long-term nature of excess weight," akin to managing conditions like hypertension.
User Testimonies
Individuals who have come off the medication report a powerful resurgence of cravings.
"I experienced something flipping and you're instantly ravenous," recalled an individual.
This difficulty is exacerbated if patients have not developed permanent dietary or behavioural modifications during therapy.
Significant Use
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is greater among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Finally, clinicians stress that while the jabs are effective tools for weight loss, they are not a standalone cure and long-term success relies on integrated behavioural management.
